MAOI & Benzodiazepine tranquilizers
Monoamine oxidase inhibitors (MAOIs) are a class of drugs that function by inhibiting the activity of the monoamine oxidase enzymes, MAO-A and MAO-B. These enzymes are responsible for breaking down monoamines, which are neurotransmitters such as serotonin, norepinephrine, and dopamine. By inhibiting these enzymes, MAOIs increase the levels of these neurotransmitters in the brain, thereby enhancing their availability and activity.
MAO-A primarily metabolizes serotonin and norepinephrine, while MAO-B preferentially breaks down dopamine and phenylethylamine. Both enzymes also degrade tyramine, a compound found in certain foods. The inhibition of monoamine oxidase allows neurotransmitters to remain in the synaptic cleft longer, facilitating greater neurotransmission. This mechanism is why MAOIs are effective in treating certain mood and anxiety disorders, including major depressive disorder and atypical depression.
There are different types of MAOIs based on their specificity for MAO-A or MAO-B and whether the inhibition is reversible or irreversible. For example, phenelzine and tranylcypromine are irreversible inhibitors that block both MAO-A and MAO-B, while selegiline primarily inhibits MAO-B at lower doses but affects both enzymes at higher doses. Moclobemide is a reversible inhibitor of MAO-A, allowing for more dietary flexibility compared to older MAOIs.
Benzodiazepine tranquilizers work by enhancing the activity of gamma-aminobutyric acid (GABA), the brain’s primary inhibitory neurotransmitter. GABA reduces neuronal excitability, promoting a calming effect on the central nervous system. Benzodiazepines bind to specific sites on the GABA-A receptor, a ligand-gated chloride ion channel, distinct from where GABA itself binds. By binding to these allosteric sites, benzodiazepines increase the receptor's affinity for GABA, resulting in more frequent opening of the chloride channel when GABA is present.
This increased chloride influx into neurons hyperpolarizes the cell membrane, making it less likely to fire action potentials. The overall effect is a reduction in neuronal excitability, which accounts for the sedative, anxiolytic, muscle-relaxant, anticonvulsant, and hypnotic properties of benzodiazepines. The specific therapeutic effect depends on the dose, duration of action, and the individual drug's pharmacokinetic properties.
For example, diazepam (Valium) is a long-acting benzodiazepine commonly used to treat anxiety, muscle spasms, and seizures. Lorazepam (Ativan) is intermediate-acting and often used for acute anxiety or as a preoperative sedative. Alprazolam (Xanax) is short-acting and frequently prescribed for anxiety and panic disorders. Midazolam (Versed) is ultra-short-acting and primarily used in medical settings for sedation during procedures.
Combining MAOIs with benzodiazepine tranquilizers can lead to several potential effects due to their interactions within the central nervous system. These effects can include intensified sedation, increased drowsiness, delayed psychomotor response, and a heightened risk of impaired coordination, which can contribute to falls or other accidental injuries. Users may also experience more pronounced central nervous system depression, potentially exacerbating respiratory depression, especially in individuals with underlying pulmonary conditions.
There is the possibility of prolonged sedation due to MAOIs interfering with metabolic pathways and the clearance of benzodiazepines, resulting in an extended duration of action and a potential buildup of these agents within the body.
In addition, mood alterations, confusion, and cognitive impairment may be more pronounced, potentially complicating other aspects of treatment or management of comorbid conditions.
Although less frequently reported, there is some concern that combining MAOIs and benzodiazepines could contribute to rare but serious reactions such as blood pressure fluctuations or other autonomic disturbances.
It's important to note that while benzodiazepines are not direct serotonergic agents, caution is advised when combining them with MAOIs due to the potential for complex interactions affecting neurotransmitter systems.
Furthermore, the risk of dependence and withdrawal symptoms upon discontinuation may be increased when both drug classes are used simultaneously.
While data remains limited, these potential effects underscore the need for heightened caution and close supervision whenever MAOIs and benzodiazepines are used together.
It's also important to highlight that MAOIs and Benzos are commonly prescribed for managing psychological and psychiatric conditions. Introducing and combining psychoactive substances during treatment with such medications generally diminishes the efficacy of the therapy, further destabilizes compromised neural systems, and elevates the likelihood of exacerbations and negative side effects.
All things considered, we recommend avoiding this combination.
Last edited by a moderator: